NIH study finds omalizumab relieves seasonal asthma attacks in youth – 4
Narrator: This is NIH Health Matters. I’m Joe Balintfy. A study of the drug omalizumab has been conducted in eight U.S. cities. Results show it nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among young people living in inner cities. Dr. Alkis Togias at the National Institute of Allergy and Infectious Diseases says the study answers a key question:
Dr. Togias: How important is allergy in children with asthma in inner-city.
Narrator: Investigators found that, overall, children and adolescents who received omalizumab had a 25 percent reduction in days with symptoms and a 30 percent reduction in asthma attacks. The findings appear in the New England Journal of Medicine. For more information, visit www.niaid.nih.gov. Health Matters is produced by the National Institutes of Health, part of the U.S. Department of Health and Human Services.
About NIH Radio
NIH Radio offers free audio news programs from the National Institutes of Health, your reliable source for health information.
All NIH Radio content is in the public domain and can be used without charge or restriction provided that it is not used to misrepresent our agency nor used to suggest we endorse any private organization, product, or service.
NIH Radio is a service of the Office of Communications & Public Liaison.